Eli Lilly says its oral weight-loss drug Foundayo, has captured more than 30 percent of new U.S. patients starting oral obesity treatments.
The claim narrows the early lead held by Novo Nordisk’s Wegovy pill.
Lilly Executive Vice President Ilya Yuffa made the statement at the Morgan Stanley healthcare conference.
Analysts expect the overall U.S. obesity treatment market to top USD 100 billion a year by 2030, so every point of new-patient share carries high stakes.
The company’s growing share reflects rising competition in the oral obesity treatment market, where convenience, pricing and supply capacity could shape the next phase of the race.
Lilly Narrows Novo’s Early Oral Lead
Novo CEO Mike Doustdar said in August that the Wegovy pill held about 90 percent of the U.S. oral obesity market. Lilly’s new 30 percent-plus claim narrows that gap, though the company has not detailed its measurement method.
At the same time, Lilly’s injectable Zepbound is gaining traction inside the U.S. Medicare obesity drug pilot that launched in July. Yuffa reported that 60 to 70 percent of enrolled patients are new to GLP-1 treatment.
Outside the United States, generic tirzepatide versions in India and Canada sell for as much as 70 percent less. Yuffa said these launches expand the overall market rather than shrink Lilly’s absolute volume for Mounjaro.
Pricing: The Affordability Story Behind the Share Numbers
- Foundayo's self-pay pricing starts at USD 149/month for the 0.8 mg and 2.5 mg doses, USD 199 for 5.5 mg, and USD 299 for the higher 9–17.2 mg doses.
- The Wegovy pill launched at the identical USD 149/month entry price, rising to USD 299 at its highest maintenance dose, as per Pharmaphorum report.
- Both drugs drop further for eligible patients as low as USD 25/month with commercial insurance, and no more than USD 50/month under Medicare's GLP-1 pilot, as per Reuters.
- Zepbound, Lilly's injectable, sits in a different bracket: USD 499 to USD 1,086.37 on the list price alone.
The Financial Backdrop: How Big Is Lilly’s GLP-1 Engine Now
- Mounjaro and Zepbound together generated USD 14.87 billion in Q2 2026 sales and accounted for 64.7 percent of Lilly’s total revenue that quarter.
- Mounjaro sales rose 91 percent year-on-year to USD 9.94 billion; Zepbound rose to USD 4.93 billion.
- Lilly’s total Q2 revenue reached USD 22.97 billion, up 48 percent, prompting the company to raise full-year 2026 revenue guidance to USD 85–87 billion.
- Foundayo itself remains a small piece of this engine, with standalone quarterly sales still around USD 100 million. The 30 percent share figure therefore tracks patient starts, not yet revenue weight.
Manufacturing: Can Lilly’s Pill Scale Faster than the Injectable?
- Lilly has committed an additional USD 4.5 billion to expand its Indiana manufacturing sites specifically to produce Foundayo and the pipeline drug retatrutide.
- Oral tablets avoid cold-chain logistics and device assembly, giving them an inherent scale advantage over injectables and supporting faster addition of new patients.
- Novo is matching the capacity push with a 432-million expansion of its Athlone, Ireland, plant aimed partly at oral GLP-1 production. Supply capacity, not only clinical data, will help decide who captures the next wave of new-patient share.
Why This Matters
Lilly’s 30 percent claim is a patient-acquisition story built on near-identical pricing, a still-modest Foundayo revenue base, and a manufacturing race that is growing more expensive. Both companies continue to expand capacity and access.
The open question neither has answered publicly is whether either side can convert oral-pill share into lasting pricing power once the market matures. Right now the contest remains about expansion, not competition on price.
